Neurocrine Biosciences
NBIX
$90.11
Share price
-1.22%
Change (1 day)
-3.62%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Earnings for Neurocrine Biosciences (NBIX)
Earnings in 2023 (TTM): $94.8 M
According to Neurocrine Biosciences 's latest financial reports the company's current earnings (TTM) are $94.8 M. In 2022 the company made an earning of $0.22 B an increase over its 2021 earnings that were of $0.12 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Neurocrine Biosciences from 2001 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | $94.8 M | -57.1% |
| 2022 | $0.22 B | 73.74% |
| 2021 | $0.12 B | -8.82% |
| 2020 | $0.13 B | 77.62% |
| 2019 | $78.53 M | 49.96% |
| 2018 | $52.37 M | -142.02% |
| 2017 | -$0.13 B | -15.44% |
| 2016 | -$0.15 B | 56.44% |
| 2015 | -$94.21 M | 46.25% |
| 2014 | -$64.42 M | 29.66% |
| 2013 | -$49.68 M | -3530.8% |
| 2012 | $1.44 M | -95.73% |
| 2011 | $33.91 M | |
| 2009 | -$47.69 M | -45.38% |
| 2008 | -$87.3 M | -58.87% |
| 2007 | -$0.22 B | 87.3% |
| 2006 | -$0.12 B | 351.97% |
| 2005 | -$25.08 M | -52.09% |
| 2004 | -$52.34 M | -10.98% |
| 2003 | -$58.79 M | -43.26% |
| 2002 | -$0.11 B | 136.12% |
| 2001 | -$43.89 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $33.18 B | 34,904.22% | 🇺🇸 USA |
 AbbVie ABBV | $9.02 B | 9,417.93% | 🇺🇸 USA |
 Eli Lilly LLY | $6.28 B | 6,527.11% | 🇺🇸 USA |
 Repligen
RGEN | $0.19 B | 108.27% | 🇺🇸 USA |
 Athersys ATHX | -$77.01 M | -181.23% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | -$34.61 M | -136.50% | 🇺🇸 USA |
 Palatin Technologies PTN | -$34.72 M | -136.62% | 🇺🇸 USA |
 Royalty Pharma RPRX | $0.79 B | 742.74% | 🇬🇧 UK |